Clinical Trials for Pancreas Cancer

A Phase I/II Open Label Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

HealthScout AI summary: Adults with previously treated locally advanced/metastatic pancreatic adenocarcinoma (post–gemcitabine/nab-paclitaxel or FOLFIRINOX; ECOG 0–2) receive oral azeliragon, a small‑molecule RAGE antagonist targeting inflammatory signaling (HMGB1/S100/AGEs), using a loading then maintenance dosing schedule in a dose‑escalation, single‑arm study. Key exclusions include ECOG >2, short life expectancy, strong CYP2C8 inhibitors, malabsorption, and significant comorbidities.

ClinicalTrials.gov ID: NCT05766748

A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate Plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine Tumors

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Single-arm study for adults with well/moderately differentiated, metastatic, unresectable, somatostatin receptor–positive pancreatic NETs (ECOG 0–2) who are PRRT- and sunitinib-naïve, allowing prior SSA and up to one prior systemic therapy. Investigates combination of lutetium Lu 177 dotatate PRRT and sunitinib (multi–TKI targeting VEGFR/PDGFR) to define safety/MTD and assess preliminary efficacy.

ClinicalTrials.gov ID: NCT05687123

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma; a Phase II Trial PANcreas CAncer RaDIofrequeNcy AbLation

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with biopsy-proven locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (ECOG 0–2, minimal prior therapy allowed) receive standard multiagent chemotherapy plus endoscopic ultrasound–guided radiofrequency ablation of the primary tumor and pembrolizumab, an anti–PD-1 antibody. Aims to test whether local ablation can enhance immune priming and systemic activity of PD-1 blockade alongside chemotherapy.

ClinicalTrials.gov ID: NCT06831136

Phase 2 Single Arm Trial Testing the ZN-c3 WEE1 Inhibitor in Combination with Gemcitabine in Second-Line Advanced Pancreatic Adenocarcinoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with unresectable/metastatic pancreatic adenocarcinoma after 1 prior platinum-based regimen (progressed or intolerant), ECOG 0–1, and measurable disease receive ZN-c3 (oral WEE1 kinase inhibitor targeting G2/M checkpoint via CDK1/2) plus gemcitabine; prior WEE1 inhibitors and prior gemcitabine in the incurable setting are excluded, with mandatory baseline and on‑treatment biopsies. Regimen: ZN-c3 Days 1–5, 8–12, 15–19 and gemcitabine IV Days 1 and 8 of 21-day cycles.

ClinicalTrials.gov ID: NCT06015659

Phase II Trial Evaluating the Safety and Efficacy of Atezolizumab in Combination With Cabozantinib for the Treatment of Metastatic, Refractory Pancreatic Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with metastatic pancreatic adenocarcinoma (ECOG 0–1) refractory to at least one fluoropyrimidine- or gemcitabine-based regimen receive atezolizumab (anti–PD-L1) plus cabozantinib (oral multi–TKI targeting MET/VEGFR/AXL). Excludes prior PD-1/PD-L1/CTLA-4 or cabozantinib exposure and patients with active autoimmune disease, uncontrolled cardiovascular/bleeding risks, or significant infection.

ClinicalTrials.gov ID: NCT04820179

A Multicenter, Open-label Phase 1/2 Dose Finding, Safety, and Pharmacokinetic Study of MBRC-201, an Antibody-drug Conjugate, in Advanced Refractory Solid Tumors

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with advanced/metastatic solid tumors refractory to standard therapy (mCRPC, metastatic breast cancer subtypes including TNBC, HR+/HER2− or HER2-low, HR−/HER2+, NSCLC, CRC, PDAC) receive MBRC-201, an investigational antibody‑drug conjugate targeting a tumor-associated antigen and delivering a likely topoisomerase I inhibitor payload. Requires ECOG 0–2 and measurable disease in expansion/Phase 2; excludes active CNS disease and prior camptothecin‑payload ADCs in later phases.

ClinicalTrials.gov ID: NCT07145255

Phase I Study of Mesenchymal Stromal Cells-Derived Exosomes With KrasG12D siRNA for Metastatic Pancreas Cancer Patients Harboring KrasG12D Mutation

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with metastatic pancreatic ductal adenocarcinoma harboring a KRASG12D mutation after prior cytotoxic therapy receive IV mesenchymal stromal cell–derived exosomes loaded with KRASG12D siRNA (iExosomes) on days 1, 4, and 10 of 14‑day cycles, up to 3 cycles with possible extension. The investigational therapy delivers siRNA via exosomes to degrade KRASG12D mRNA and suppress downstream MAPK signaling; eligibility requires ECOG 0–1 and adequate organ function, with treated/stable brain metastases permitted.

ClinicalTrials.gov ID: NCT03608631

Intraperitoneal Paclitaxel With Standard Systemic NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis: Prospective Pilot Trial

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with pancreatic ductal adenocarcinoma limited to the peritoneum (PCI ≤8, ECOG 0–1), including resectable/borderline/locally advanced disease and select patients with up to 4 months of prior FOLFIRINOX/NALIRIFOX without progression, receive intraperitoneal paclitaxel (microtubule stabilizer) on days 1 and 8 plus systemic NALIRIFOX (5-FU/leucovorin, liposomal irinotecan [topoisomerase I inhibitor], oxaliplatin) on day 1 of 14-day cycles up to 12 cycles. The trial evaluates safety and signals of efficacy, with goals of peritoneal disease control and potential conversion to surgery.

ClinicalTrials.gov ID: NCT07030283

A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves patients with advanced or metastatic solid tumors expressing Nectin-4, including urothelial carcinoma, triple-negative breast cancer, non-small cell lung cancer, and ovarian cancer, who have exhausted standard therapy options. It evaluates LY4052031, an antibody-drug conjugate that targets Nectin-4 to deliver a topoisomerase I inhibitor, aiming to assess its safety, tolerability, and efficacy in these patients.

ClinicalTrials.gov ID: NCT06465069

Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves patients with locally advanced or metastatic pancreatic, lung, breast, and colorectal cancers who have progressed after standard treatments and exhibit tumor uptake of [68Ga]Ga-NNS309. It evaluates the safety and preliminary activity of the investigational radioligand [177Lu]Lu-NNS309, which targets specific tumor markers, though its exact mechanism of action is undisclosed.

ClinicalTrials.gov ID: NCT06562192